Biocompatible Peritoneal Dialysis Solutions
- 1 April 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 5 (4), 723-732
- https://doi.org/10.2215/cjn.05720809
Abstract
Clinical experience and literature evidence suggest that peritoneal dialysis (PD) is a safe and effective treatment in short term (3 to 5 years) for stage 5 chronic kidney disease patients. A major limitation to long-term PD has been peritoneal membrane structural and functional alterations over time, resulting in significant technique failure. Much evidence implicates glucose contained in conventional PD solutions as the major cause of membrane changes. Other harmful characteristics of glucose or its degradation products are thought to cause systemic undesirable metabolic and cardiovascular effects. This led to the search for more “biocompatible” PD solutions to ameliorate complications associated with conventional glucose solutions. Studies in animals and humans show that newer biocompatible solutions may preserve membrane functions better, lead to less therapy failure, and avoid the undesirable metabolic and cardiovascular effects of systemic glucose exposure. There is evidence in specific, clinical, short-term situations of biochemical and metabolic benefits of biocompatible solutions. However, are these solutions superior to glucose in preserving peritoneal membrane long term? Are they truly more biocompatible? Clinical and experimental data suggest that newer solutions, albeit most of them glucose based, are less toxic compared with the current PD solution; however, there is currently no osmotic agent that can safely replace glucose. The future appears to be in using combinations of different osmotic agents in a more biocompatible solution, whether they are mixtures in a single bag or daily exchanges of different osmotic agents. This review discusses the current status of these biocompatible solutions in PD patients.This publication has 110 references indexed in Scilit:
- Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchangeNephrology Dialysis Transplantation, 2008
- Effects of Icodextrin on Glycemic and Lipid Profiles in Diabetic Patients Undergoing Peritoneal DialysisAmerican Journal of Nephrology, 2007
- Peritoneal Dialysis with Solutions Containing Amino Acids Plus Glucose Promotes Protein Synthesis during Oral FeedingClinical Journal of the American Society of Nephrology, 2007
- The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patientsClinical Nephrology, 2006
- Dialysate as FoodJournal of the American Society of Nephrology, 2005
- Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patientsKidney International, 2004
- Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentrationKidney International, 2003
- Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patientsClinical Nephrology, 2002
- Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearanceNephrology Dialysis Transplantation, 1997
- Lymphatic Absorption in CAPD Patients with Loss of Ultrafiltration CapacityBlood Purification, 1995